Patent Board Denies Review Of Patents Related To Natalizumab
ALEXANDRIA, Va. — Three petitions for inter partes review (IPR) of patents covering the immunosuppressant drug natalizumab — marketed under the brand name “Tysabri” — were denied Oct. 17 by the...To view the full article, register now.
Already a subscriber? Click here to view full article